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ABSTRACT  
Background: Cyst growth of BD-IPMNs on follow-up imaging remains a concerning sign.  
Aims: To describe cyst size changes over time in BD-IPMNs, and determine whether cyst growth rate is associated with increased risk 
of malignancy.  
Methods: This is a retrospective study performed at two high volume tertiary centers. Mean cyst size at baseline (MCSB) and mean 
growth rate percentage (MGRP) were calculated. Rapid cyst growth was defined as MGRP ≥ 30%/year. Patient and cyst related 
characteristics were studied. 
Results: 160 patients were followed for a median of 27.4 (12-114.5) months. MCSB was 15.1±8.0 mm. During follow-up, 73 (45.6%) 
showed any cyst size increase, of which 15 cysts (9.4%) exhibited MGRP ≥ 30%/year. Rapid cyst growth was not associated with 
patient or cyst characteristics. Cyst fluid molecular analysis from 101 cysts showed KRAS mutation in 26. Compared to KRAS-
negative cysts, neither MCSB (16.0 mm vs. 17.7 mm; p=0.3) nor MGRP (3.9%/year vs. 5.8%/year; p=0.7) was significantly different.  
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advanced neoplasia had MGRP ≥ 30%/year. 
Conclusion: Increase in BD-IPMNs size was not associated with the known high risk patient or cyst-related characteristics. Rapid 
growth of BD-IPMNs was not associated with advanced neoplasia on surgical pathology. 
Keywords: branch-duct IPMN (BD-IPMN); endoscopic ultrasound; cyst growth rate; CT; MRI; molecular analysis; Dysplasia; 
neoplasia 
1. Introduction
Branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) are the most common variant of IPMNs and are most 
often detected incidentally in patients undergoing abdominal imaging. Fortunately, the majority of incidental BD-IPMNs are low risk 
lesions where management has evolved to become more conservative in the recent years. According to the 2017 revised International 
consensus guidelines (ICG) for the management of IPMNs [1], the indications for surgical resection include main-duct IPMNs (MD-
IPMNs) and BD-IPMNs with high risk stigmata. Cyst size exceeding 3 cm is no longer an indication for resection as initially proposed 
in the 2006 ICG [2], and a rapidly increasing cyst size (> 5mm/2years) is proposed as a new high risk factor for malignancy based on 
earlier studies [1]. 
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neoplastic pancreatic cysts recommend that patients with both a solid component and a dilated pancreatic duct (PD) and/or concerning 
features on endoscopic ultrasound (EUS)-fine-needle aspiration FNA) should undergo surgery to reduce the risk of mortality from 
carcinoma [3].  Although previous studies endorsed rapid cyst growth as a high risk feature and recommended resection be considered 
for these lesions [4,5], the AGA guidelines suggest that an increase in cyst size alone should not be considered a significant risk factor 
for malignancy [6]. The validity of cyst size alone in predicting malignancy has been scrutinized by recent studies; the results of which 
were controversial [7,8]. 
The aims of this study were to describe cyst size changes over time in patients with BD-IPMNs, and to determine whether cyst growth 
rate can be associated with risk of malignancy in a multicenter setting.  
2. Materials and Methods
2.1. Study Population 
This is a retrospective study performed at two high volume tertiary centers. Using our prospectively maintained EUS database, we 
identified all patients with a diagnosis of a BD-IPMN at Indiana University Hospital (IUH) and Thomas Jefferson University (TJU) 
between January 2001 and December 2013. Patients were included if they were followed for at least 12 months and underwent cross-
sectional imaging (CT scan or MRI/MRCP) at least twice during the follow-up period. In patients only surveyed by imaging, the 
diagnosis of BD-IPMN was established by EUS with/without FNA confirming one or more dilated branch ducts communicating with 
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molecular analysis was performed, the presence of a K-ras point mutation was considered sufficient for the diagnosis of a BD-IPMN 
lesion when ductal communication was present [10]. Surgical pathology was the reference standard in patients who underwent 
surgery. Patients found to have concomitant main pancreatic duct (MPD) involvement on imaging or resection pathology were 
excluded. Based on pathology, noninvasive IPMNs were subcategorized into low-grade or high-grade dysplasia, based on the maximal 
degree of dysplasia in the lining epithelium. Invasive IPMNs were subcategorized into minimally or grossly invasive lesions. To 
simplify study outcomes, BD-IPMNs were further classified into benign (low- or moderate-grade dysplasia) or malignant tumors 
(high-grade dysplasia or invasive cancer) based on the World Health Organization (WHO) classification [11]. Patients’ medical 
records were reviewed to obtain demographic data, clinical presentation, medical history, family history, social history, cysts 
characteristics by cross-sectional imaging and/or EUS. The study period was defined as the interval between the index imaging (initial 
diagnosis) and the most recent available imaging and clinical follow-up, with an attempt to obtain a minimum of 12-month follow-up 
with 2 or more serial imaging. Surgical pathology results were documented in patients who underwent surgery. Long-term clinical 
follow-up after the index imaging was obtained by review of the medical records and all available serial imaging. Patient-specific 
factors such as smoking, alcohol consumption, cyst-related symptoms, and family history of pancreatic cancer were collected. Cyst-
related characteristics such as location, multiplicity, presence of septations or nodules, cyst fluid CEA and molecular analysis results 
were recorded. The study protocol was approved by the Institutional Review Board of the two respective institutions. 
2.2. Cyst size measurement 
Based on the 2017 revised ICG, cyst size calculations were based on contrast enhanced CT or gadolinium-enhanced MRI [1]. If a 
patient had both CT and MRI performed over multiple points of time, we adopted only one of them over the follow-up period to 
minimize measurement variation between different imaging modalities. Since most cysts were not exactly spherical, cyst “size” on 
imaging studies was calculated by averaging the major and minor axis dimensions. This includes the sum of maximum dimensions in 
multiloculated lesions. For multifocal lesions, the largest cyst only was included in the study. After obtaining imaging data, cyst 
growth (mm) was calculated by final cyst size (mm) – initial cyst size (mm). Mean growth rate (MGR) was calculated as cyst growth 
per year. Mean cyst growth rate percentage (MGRP) per year was calculated as a percentage from the following formula which takes 
into account baseline cyst size and time during which the cyst growth occurred: 
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Rapid cyst growth was defined as a mean MGRP ≥ 30%/year based on a previously published study by Kang et al where he found that 
malignant BD-IPMN grew significantly faster than benign BD-IPMN with a mean annual percentage of cyst growth rate of 29.6 
%/year [4].  
2.3. Cyst fluid analysis 
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The following cyst characteristics were recorded: cyst location, MPD diameter and communication, septations, cyst wall thickness, 
calcifications, presence of mural nodules and associated solid mass. EUS was performed using linear echoendoscopes (32UA or 32 
UX, Pentax Medical Co, Montvale, NJ; GF-UC30P or GF-UC140P, Olympus America, Inc., Center Valley, PA) with or without 
radial echoendoscopes (GF-UM20, GF-UM130, or GF-UM160, Olympus America, Inc., Center Valley, PA). FNA was performed 
using 19-, 22- or 25-gauge needles with the presence of on-site cytopathology. The aspirated fluid was processed on site for cytology 
slides. Allocation of cyst fluid for CEA, or molecular analysis was performed at the discretion of the endosonographer based on the 
volume obtained. Molecular analysis of cyst fluid, if performed (carried out by the former PathFinderTG/Pancreas; RedPath Integrated 
Pathology, Inc., Pittsburgh, Pennsylvania, USA, and currently Interpace Diagnostics), included DNA quantity and quality, KRAS 
point mutation, and tumor suppressor genes (loss of heterozygosity -LOH) [12]. 
2.4. Surgical indications 
Surgical resection was recommended if patients developed symptoms related to the cysts, or in the presence of suspicious features on 
imaging and/or EUS-FNA, and if patients were fit for surgery. For BD-IPMNs diagnosed before 2006, suspicious features for 
malignancy included cyst size ≥ 3 cm, MPD dilation (≥ 10 mm), presence of solid component, cytologic evidence of high-grade 
dysplasia, or positive cytology for malignancy. For BD-IPMNs diagnosed between 2006 and 2013, suspicious features for malignancy 
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considered every 3-12 months based on the baseline findings on index imaging. 
2.5. Statistical Analysis 
Statistical analysis was performed using SPSS 21.0 for Windows software (SPSS, Chicago, IL, USA). Continuous variables were 
reported as mean ± standard deviation (SD). Categorical variables were presented as numbers and percentages. The Student’s t-test 
was performed for continuous variables and chi-square or Fisher’s exact test for categorical variables. Linear regression was used to 
estimate correlation between baseline cyst size and MGRP. A p value < 0.05 was considered statistically significant. 
3. Results
Between January 2001 and December 2013, 287 patients with pure BD-IPMNs were identified from the IUH database and 87 patients 
from the TJU database (Fig. 1). One hundred sixty six patients from the first database and 48 patients from the second database, with 
follow-up less than 12 months or fewer than 2 serial imaging studies, were excluded. One hundred and sixty patients met the study 
criteria and were included in the analysis.  
3.1. Patient and Cyst characteristics 
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median follow-up was 27.4 (range, 12-114.5) months.  MRI/MRCP was the most commonly performed index and surveillance 
imaging study (230) followed by EUS (75) then CT (68). All patients underwent EUS either at baseline or during follow-up most of 
which underwent FNA (153/160). Molecular analysis was performed in 101 (63.1%) patients.  
Cysts’ characteristics are summarized in Table 2. Eighteen patients underwent surgery during follow up of whom 15 (83) had low 
grade dysplasia (LGD), and 3 had advanced neoplasia (1 high grade dysplasia and 2 with invasive carcinoma) on pathology. 
The mean cyst size at baseline (MCSB) was 15.1 ± 8.0 mm. The mean cyst growth rate (MGR) was 0.58 ± 4.33 mm/year. The mean 
growth rate percentage (MGRP) was 5.68 ± 24.89 %/year. Seventy three (45.6%) patients had cyst size increase of a minimum of 1 
mm, of whom 15 (9.4%) patients had a MGRP ≥ 30 %/year occurring more in older patients (70.8 vs. 64.1 years; p=0.03). Eighty 
seven patients (54.4%) did not have cyst size increase (Table 3). The distribution of number of cysts by the percentage of MPGR is 
illustrated in Figure 2.  
Cyst characteristics and surgical status according to follow up duration are summarized in Table 4. Cysts growing rapidly were found 
to be followed for a shorter duration of time. 
3.2. Correlation between MGR, MGRP and Patient and Cyst Characteristics 
AC
CE
PT
ED
 M
AN
US
CR
IPTRapid cyst growth did not correlate with patient-specific factors such as smoking, alcohol consumption, development of interval 
symptoms, or family history of pancreatic cancer. Rapid cyst growth did not correlate with cyst characteristics such as number 
(unifocal vs multifocal), presence of septations or nodules, cyst fluid CEA level > 192 ng/ml, and molecular analysis results (Table 5). 
As noted above, cyst fluid from 107 patients was sent for DNA analysis and showed KRAS mutation in 27. Compared to KRAS-
negative cysts, neither MCSB (16.0 mm vs 17.7 mm; p=0.3) nor MGRP (3.9%/year vs 5.8%/year; p=0.7) was significantly different. 
Similar observations were found in cysts with high DNA content (≥40ng/ul), good quality DNA or ≥2 allelic imbalance (LOH) 
mutations. Rapid cyst growth (MGRP ≥ 30%/year) was similar between the surgical and non-surgical groups (16.7% vs 8.5%; 
p=0.26). Only one of the 3 patients with rapid cyst growth in the surgical group had invasive carcinoma on pathology, while the other 
2 had LGD. MCSB was not statistically different in the surgical group compared to the non-surgical group (17.5 vs. 14.7; p= 0.29) and 
in the advanced neoplasia subgroup compared to those with low-grade dysplasia (20.0 vs. 17.07; p= 0.67). Cysts growing ≥2 mm/year 
but not with MGPR ≥ 30%/year were resected more often than those that regressed or grew at a slower rate (32.3% vs 6.2%; p<0.001) 
(Table 5). Otherwise cysts growing ≥2 mm/year behaved similar to those with MGPR ≥ 30%/year with respect to correlation with 
significant patient or cyst characteristics. Linear regression showed that smaller cysts did not grow at a faster rate (R2=2%; p=0.07) 
compared to larger ones (Fig. 3).  
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Over the past 2 decades, pancreas cyst detection has increased secondary to an aging population, advancements in imaging technology 
and their overutilization for a variety of health-related purposes. This led to a flurry of incidental pancreatic lesions detected, the vast 
majority of which are low risk but result in subjecting patients to prolonged imaging surveillance. In the absence of reliable cyst fluid 
biomarkers or accurate imaging predictors of malignancy, consensus statements and societal guidelines have been developed to 
address management of pancreatic cysts neoplasms [14]. The approach to pancreatic cysts has changed over the last decade in regards 
to the utilization of EUS-FNA. The 2005 ASGE guidelines, for example, recommended EUS-FNA of all cysts for cyst fluid analysis 
and cytology [15]. The 2006 ICG on the other hand called for more selective use of EUS based on cyst size and presence of 
worrisome features in IPMNs and MCNs [2]. The  2015 AGA guidelines for asymptomatic cysts recommended EUS examination 
only in the presence of 2 high-risk stigmata (cyst size  ≥ 30 mm, dilated MPD, solid component), and surgical referral in the presence of 
malignant cytology on EUS-FNA or at least 2 high-risk features (cyst size ≥ 30 mm, dilated MPD, solid component) [16]. The 2012 
ICG and the 2017 revised ICG similarly recommended EUS for the evaluation of worrisome features but cyst size alone became less 
of a concern [1,13]. This reflects better understanding of the natural history of pancreatic cysts in general, and clearly elevated the 
threshold for EUS-guided sampling or surgical resection, shifting management paradigms towards more conservative strategies. 
Accordingly, magnetic resonance imaging (MRI) is increasingly recommended for periodic surveillance to avoid excessive radiation 
exposure during CT examinations. 
AC
CE
PT
ED
 M
AN
US
CR
IPTThe guidelines, however, did not clearly address lesions that continue to grow slowly or grow considerably in a short time to identify a 
threshold to repeat EUS sampling or surgical resection during surveillance of such lesions. This continues to be a dilemma to many 
clinicians due to long-term cost implications of intensive imaging surveillance, or the morbidity related to surgical resection. Most 
recently the revised ICG 2017 guidelines defined rapid cyst growth as growth of > 5 mm/2 years and considered this to be a 
worrisome feature that requires shorter interval surveillance [1]. It is worth noting that the definition of rapid cyst growth was based on 
few retrospective series [4,5,17,18] with different definitions of rapid cyst growth and conflicting data around the correlation 
between cyst growth and the grade of dysplasia in the lesion (Table 6). Interpretation of the results of such series is also limited by the 
relatively short duration of follow-up and the small number of patients. Also the definition of rapid cyst growth as > 5 mm/2 years 
does not account for baseline cyst size which in our opinion should weigh in the value of rapid cyst growth. Our study adds to existing 
literature on this topic and summarizes our multicenter experience in managing pancreatic cysts that grow over time in the context of 
specialized multi-disciplinary pancreas cyst programs. 
Natural history of IPMN is increasingly described in literature. Review of 4 series [4,19-21] on BD-IPMNs showed an overall increase in 
cyst size in 2-10% and invasive cancer rates of up to 6.3%. Similarly, Woo et al. [17], in a single center study on 190 patients with BD-
IPMNs, noted an increase in cyst size in 11 (10.5%) of 105 patients followed without surgery, and invasive cancer in 1 (0.8%) of 124 
patients initially managed conservatively.  Authors concluded that a simple increase in cyst size in the absence of suspicious 
features on imaging during follow-up is not a reliable predictor of malignancy in BD-IPMN. On the other hand, Yamaguchi et al. [22] 
showed that an increase in the BD diameter was significantly associated with invasive cancer compared with carcinoma in situ. An 
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malignant BD-IPMNs with 81% accuracy. In a retrospective study of 121 patients with BD-IPMNs, Rautou et al. [5] concluded that 
the only factor associated with signs of progression to malignancy was an increase in cyst size to more than 5 mm during the follow-
up evaluation regardless of baseline cyst size and duration of follow up, with a 5-year cumulative risk of 38% vs.  8% (p=.003). Two 
years later, researchers from the same institution followed the natural history of BD-IPMN using serial CT scan and surgical 
pathology from 201 patients with BD-IPMNs [4].  Cyst growth rate ≥ 2 mm/year had 3- and 5-year cumulative risks of malignancy of 
6.4% and 45.5%; whereas cyst growth rate < 2mm/year had corresponding risks of 1.8% and 1.8% respectively (p < .001). More 
recently, Kwong et al. [18] further studied the clinical implications of cyst growth rate in a retrospective multicenter study of 284 
patients with BD-IPMNs. All patients underwent EUS evaluation followed by surveillance imaging.  Cyst growth rate between 2 and 
5 mm/year was associated with an increased risk of malignancy with hazard ratio (HR) of 11.4 when compared to subjects with cyst 
growth < 2 mm/year (p=.0004). Cyst growth ≥ 2 mm/year had a sensitivity of 78%, specificity of 90%, and accuracy of 88% to 
identify malignancy. Total cyst growth ≥ 10 mm had a sensitivity of 100%, specificity of 95%, and accuracy of 88% to identify 
malignancy. Using percentage growth (total growth/initial size) to assess the presence of malignancy produced an area under ROC 
curve of 0.91. The optimal cutoff was 40% BD-IPMN growth, which produced a sensitivity, specificity, and accuracy of 78, 84, and 
84% respectively.  However, surveillance was not standardized as this was a retrospective study across 4 centers. Follow-up imaging 
was generally recommended on at least a yearly basis, though patients and referring physicians did not necessarily adhere to these 
recommendations. Besides, this study (and all the above-mentioned studies) used CT, MRI/MRCP, and/or EUS interchangeably as 
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(3 to 4 mm) of pancreatic cysts by different imaging modalities (CT, MRCP, EUS) has been previously described [23]. Attempts to 
detect a 2-mm difference on imaging are vulnerable to human errors in measurement, measurement of the cyst at different cross-
sections, and variability inherent to the physical features of the imaging modalities. This should be taken into account when making 
management decisions.  Therefore, the use of a single imaging modality is recommended during follow-up, and a high specificity 
should be sought when evaluating BD-IPMN for malignancy to avoid unnecessary resections. In our study, we took into consideration 
the above-mentioned limitations and adopted the same imaging modality for follow-up to avoid the variation is size estimates.  
In our study, we further evaluated the significance of cyst growth using a mean cyst growth rate percentage (MGRP).  We believe that 
growth rate should be reflected as a proportion averaged over the number of years the cyst is surveyed (%/year) to account for baseline 
cyst size and hedge against year-to-year size fluctuations. We chose an MGRP cutoff of ≥ 30%/year to be significant [5]. Our study 
shows that a MGR ≥ 2mm/year or MGRP ≥ 30%/year was not associated with known high risk patient or cyst characteristics. More 
importantly, there was no association between MGPR and tumor markers or degree of dysplasia on surgical pathology, in contrast to 
some of the studies discussed above [4,5,18]. We believe that our definition of “rapid cyst growth” factors in longer term observations 
along with a more complete account of patient and cyst characteristics.  
Similar to previous studies, we showed that any cyst size increase over time is rather common; occurring in more than 40% of patients 
with BD-IPMNs, fifth of whom had significant growth. We could not reproduce the previous observation that small cysts grew at a 
faster rate than larger ones [4]. Our results are, in principle, supportive of recently published data demonstrating significant 
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Understanding factors affecting the internal cyst milieu, and how this relates to cyst growth, requires further study. 
Our goal is not to discourage surveillance for small pancreatic cysts but to shed light on the true clinical significance of cyst growth in 
small BD-IPMN lacking high-risk stigmata. We are aware of previous studies where baseline BD-IPMN cyst size alone failed to 
predict malignancy [24-26]. Similarly, the current study demonstrated that rapid cyst growth may not be an indicator of malignant 
transformation in small low risk BD-IPMNs and that the algorithm of management of BD-IPMN outlined by the 2012 ICG may need 
further examination. In some aspects, our results support the more recent AGA guidelines in adopting more than one high risk 
morphological feature (beyond size) as an indication for EUS-guided sampling or referral to surgery.  
We also report that the rapid cyst growth tends to occur in older patients (70.8 vs. 64.1 years; p=0.03). The relationship between age 
and malignant cyst outcome remains unclear based on the current literature. Symptomatic patients presumed to be related to cysts and 
cysts growing > 2mm/year seem to undergo surgical resection more often than asymptomatic patients and slower growing cysts 
despite no significant difference on final surgical pathology according to at least one study [27]. In our study, cysts growing rapidly 
were found to be followed for a shorter duration. We believe that rapid cyst growth is caught early during surveillance in agreement 
with the 2017 revised International consensus guidelines (ICG) for the management of IPMNs that had diminished first follow up 
surveillance from 12 months to 6 months. 
We recognize several limitations to our study, including the intermediate-term follow-up, retrospective design and tertiary center 
referral bias. In addition, the EUS procedures and the management of these patients were performed by expert endoscopists in the 
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Furthermore, endoscopists were aware of the clinical history and this may have influenced their management and decision making. 
Cyst sizes in the current study were calculated by averaging the major and minor axis dimensions which is less accurate than three-
dimensional volume measurement of cystic lesions. Most lesions are not exactly spherical in shape, and determining the volume of an 
irregular lesion is difficult and impractical. Additionally, no central radiology review was constructed as part of the study which would 
have been impractical due to the large number of radiological exams involved (over 3000). We chose mean cyst growth rate 
percentage (MGRP) ≥ 30%/year to be significant based on limited published evidence [4]. However, we provided a superior 
mathematical definition of rapid cyst growth accounting for baseline cyst size and time window of cyst surveillance. We also analyzed 
different thresholds for rapid cyst growth such as ≥ 2mm/year which was recently adopted by the 2017 revised ICG. Finally, our 
sample size was smaller than that of other published studies but this related to our stringent inclusion criteria of only patients that 
underwent EUS evaluation plus FNA of cystic fluid for most patients (95.6%). This stemmed from our knowledge of the limited 
diagnostic power of CT for pancreatic cyst and that EUS is the tool of choice for such lesions [28]. This has ensured that our studied 
population is truly comprised of only BD-IPMN and not other cysts of similar radiologic characteristics that could have undoubtedly 
been misclassified and included in previous BD-IPMN studies giving our results more credibility and accuracy. Given the above 
limitations, the validity of our findings should be confirmed in a prospective and longitudinal study.  
In summary, we reported our experience in a diverse patient population with BD-IPMNs. Our study demonstrates that cyst growth is 
common over time in patients with BD-IPMNs undergoing surveillance imaging. Rapid cyst growth is not associated with known 
high-risk patient or cyst characteristics as well as advanced neoplasia on surgical pathology and thus unlikely to represent a worrisome 
feature.  
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Legends 
Fig. 1 Flowchart 
BD, branch duct; IPMN, intraductal papillary mucinous neoplasm; pts, patients, MGRP, mean growth rate percentage. 
Figure 1. Flowchart. BD, branch duct; IPMN, intraductal papillary mucinous neoplasm; pts, patients, MGRP, mean growth rate percentage.
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Fig. 2 Number of cysts categorized by growth rate. 
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Fig. 3 Linear regression analysis of growth rate with respect to baseline cyst size. 
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Table 1 Patients’ characteristics. 
N = 160 
Mean age, years ± SD 64.6 ± 12.0 
Sex, no. (%) 
    Male 
    Female 
64 (40%) 
96 (60%) 
Smoking (active or past use) 29 (20.7%) 
Alcohol use (active or past use) 47 (33.3%) 
Clinical symptoms related to BD-IPMN 
   Acute pancreatitis  
    Chronic pancreatitis 
    Others symptoms 
    Asymptomatic  
30 (20.8%) 
6 (4.2%) 
24 (16.7%) 
84 (58.3%) 
Family history of pancreas cancer 2 (1.3%) 
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Table 2 Cysts’ characteristics. 
N (%) 
Focality 
    Unifocal 
    Multifocal 
139 (86.9%) 
21 (13.1%) 
Location 
    Head  
    Body 
    Tail  
    Uncinate process 
    Neck 
67 (41.9%) 
48 (30.0%) 
26 (16.3%) 
12 (7.5%) 
7 (4.4%) 
Septations 73 (45.6%) 
Nodule(s) 5 (3.1%) 
Mass component 1 (0.7%) 
Cyst fluid analysis 
    Mean CEA level, ng/mL ± SD 
    Molecular analysis 
 DNA quantity ≥ 40 ng/ul 
 DNA quality: good 
 KRAS point mutation 
 LOH ≥ 2 allelic imbalance mutations 
2422.14 ± 6207.87 
101 (68.2%) 
    8 (7.9%) 
    25 (38.5%) 
    26 (26%) 
    8 (8.2%) 
Surgical pathology 
    Low grade dysplasia  
    High grade dysplasia 
    Invasive cancer 
18 (11.3%) 
    15 (83.3%) 
    1 (5.6%) 
    2 (11.1%) 
LOH, Loss of heterozygosity. AC
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Table 3 Cysts’ size, growth rate, and growth rate percentage. 
MCSB, MGR, MGRP Mean ± SD 
MCSB, mm ± SD 15.10 ± 8.03 
MGR, mm/year ± SD 0.58 ± 4.33 
MGRP, %/year ± SD 5.68 ± 24.89 
Cyst size variation N (%) 
Increased 73 (45.6%) 
     MGR ≥ 2mm/year 31 (19.4%) 
     MGR ≥ 5mm/year 16 (10.0%) 
     MGRP ≥ 30%/year 15 (9.4%) 
Stable or decreased 87 (54.4%) 
MCSB, Mean cyst size at baseline; MGR, Mean cyst growth rate; MGRP, Mean growth rate 
percentage 
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Table 4. Cyst characteristics and surgical status according to follow up duration. 
Follow up Duration 
< 27 months 
N=80 
 27 months
N=80 
P value 
Surgery performed 12 (15.0%) 6 (7.5%) 0.13 
Cyst size increased 38 (47.5%) 35 (43.8%) 0.63 
MGRP ≥ 30%/year 13 (16.3%) 2 (2.5%) 0.03 
MGR ≥ 2mm/year 23 (28.8%) 8 (10.0%) 0.03 
CEA level > 192 ng/ml 26 (53.1%) 21 (56.8%) 0.73 
DNA quantity ≥ 40 ng/ul 7 (12.7%) 1 (2.2%) 0.05 
DNA quality: good 16 (50.0%) 9 (27.3%) 0.06 
KRAS point mutation 12 (22.2%) 14 (30.4%) 0.35 
LOH ≥ 2 allelic imbalance mutations 4 (7.7%) 4 (8.9%) 0.83 
MGR, Mean cyst growth rate; MGRP, Mean growth rate percentage; LOH, loss of heterozygosity; CEA, carcinoembryonic antigen 
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Table 5 Correlation between MGR, MGRP and Patients’ and Cysts’ Characteristics. 
MGR <2mm/year 
(N=135) 
MGR ≥2mm/year 
(N=25) 
P value MGRP < 30%/year 
(N=145) 
MGRP ≥30%/year 
(N=15) 
P value 
Patient characteristics 
Male 
Female 
Smoking 
Alcohol use 
Clinical symptoms related to BD-IPMN 
Family history of pancreas cancer 
45 (34.9%) 
84 (65.1%) 
22 (19.3%) 
37 (32.2%) 
47 (39.8%) 
9 (9.5%) 
19 (61.3%) 
12 (38.7%) 
7 (26.9%) 
10 (38.5%) 
13 (50.0%) 
0 
0.007 
0.37 
0.54 
0.34 
0.17 
56 (38.6%) 
89 (61.4%) 
26 (20.3%) 
44 (34.1%) 
54 (59.1%) 
9 (8.9%) 
8 (53.3%) 
7 (46.7%) 
3 (25.0%) 
3 (25.0%) 
6 (50.0%) 
0 
0.27 
0.70 
0.52 
0.54 
0.08 
Mean age (years) 64.2 66.5 0.35 64.0 70.8 0.03 
Cyst characteristics 
Unifocal  
Septations 
Nodule(s) 
Mass component 
Cyst fluid analysis 
     CEA > 192 ng/mL 
    Molecular analysis 
        DNA quantity ≥ 40 ng/µl 
        Kras point mutation 
        LOH ≥ 2  
Surgical resection performed 
        Benign/malignant 
110 (85.3%) 
58 (45.0%) 
3 (2.9%) 
0 
32 (51.6%) 
5 (6.3%) 
20 (25.6%) 
6 (7.8%) 
8 (6.2%) 
7/1 
29 (93.5%) 
15 (48.4%) 
2 (10.5%) 
1 (3.6%) 
15 (62.5%) 
3 (13.6%) 
6 (27.3%) 
2 (10.0%) 
10 (32.3%) 
8/2 
0.22 
0.73 
0.13 
0.04 
0.36 
0.26 
0.88 
0.75 
0.00 
0.65 
125 (86.2%) 
66 (45.5%) 
4 (3.7%) 
0 
41 (53.2%) 
6 (6.5%) 
24 (26.1%) 
6 (6.7%) 
15 (10.3%) 
13/2 
14 (93.3%) 
7 (46.7%) 
1 (8.3%) 
1 (7.7%) 
6 (66.7%) 
2 (25.0%) 
2 (25.0%) 
2 (28.6%) 
3 (20.0%) 
2/1 
0.44 
0.93 
0.44 
0.001 
0.44 
0.06 
0.95 
0.05 
0.26 
0.40 
MGR, Mean cyst growth rate; MGRP, Mean growth rate percentage; LOH, loss of heterozygosity; CEA, carcinoembryonic antigen AC
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Table 6 Summary of published studies evaluating the correlation between cyst size/growth and malignant outcomes. 
Author Rautou et al.5 Woo et al.17 Kang et al.4 Kwong et al.18 Current  
Year of publication 2008 2009 2011 2015 2017 
Country France South Korea South Korea U.S. x 4 U.S. x 2 
Type of study Retrospective Retrospective Retrospective Retrospective Retrospective 
Period of time 1999-2005 1998-2005 2000-2009 2002-2011 1996-2013 
Center(s) Single center Single center Single center Multicenter Multicenter 
Number of patients 121 190 201 284 160 
Male/Female 32/89 111/79 111/90 123/161 64/96 
Mean age (years) 63 63 62.6 67 64.69 
Surveillance 104 105 166 272 150 
Surgery Benign 17 13 85 71 35 27 12 3 18 15 
Malignant 4 14 8 9 3 
Follow-up (months) 
Median 
Range 
33 
12-94
25 
6-86
27.9 
3.2-109.5 
56 
36-74
27.4 
12-114.5
Imaging CT, MRCP, EUS CT, MRCP, EUS, ERCP CT, MRCP, EUS, ERCP CT, MRCP, EUS CT, MRCP, EUS +/- FNA 
Standard for diagnosis First 3 years of f/up: 
Alternated imaging every 8 
months 
After 3 years: yearly 
>2 imaging studies CT 
Every 3-6 months-first year 
Then every 9-12  months 
At least 2 cross-sectional 
imaging 6 months apart 
At least 2 cross-sectional 
imaging; minimal of 6 
months of surveillance 
Cyst size {average of major 
and minor axis diameter on 
axial images) 
Yes Yes Yes Yes Yes 
Criteria Increase in cyst size > 5 
mm (between diagnosis 
and end of f/up period) 
Increase in cyst size ≥ 20% Cyst growth rate ≥ 
2mm/year 
Cyst growth rate ≥ 
2mm/year 
MGRP ≥30% 
Total growth ≥10 mm 
% growth > 40 % 
Conclusion Cyst size increase by  more 
than 5 mm during the 
follow-up suggested 
malignant progression 
Not a reliable predictor of 
malignancy in the absence 
of other suspicious 
features on imaging 
Predicts high risk of 
malignancy 
Predicts high risk of 
malignancy 
Cyst growth is common 
over time 
Rapid cyst growth not 
associated with high risk 
patient and cysts 
characteristics, and 
advanced neoplasia on 
surgical pathology 
Se 78 Sp 90 A 88 
Se 100 Sp 95 A 95 
Se 78 Sp 84 A 84 
Se: sensitivity; Sp: specificity 
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